TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Trial to Compare Radiation Therapy Alone With Radiation Therapy and Concomitant Anti-EGFr Antibody (C225) for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if radiation therapy is more effective with or without cetuximab for cancer of the oropharynx, hypopharynx, or larynx.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without cetuximab in treating patients who have stage III or stage IV cancer of the oropharynx, hypopharynx, or larynx.


Options:
A: Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Radiotherapy 70 Gy, 35 fractions; Assigned to Arm(s): N/A
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Radiation: intensity-modulated radiation therapy (IMRT), Drug: Paclitaxel, Drug: Cisplatin | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Radiation: intensity-modulated radiation therapy (IMRT), Drug: Paclitaxel, Drug: Cisplatin | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy (IMRT); Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Group 1, Group 2
C: Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II
D: Arm Label: Cetuximab Plus Chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU) | Arm Label: Chemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Platinum (Cisplatin or Carboplatin) + 5-FU | Intervention Type: DRUG; Name: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU); Assigned to Arm(s): Cetuximab Plus Chemotherapy | Intervention Type: DRUG; Name: Platinum (Cisplatin or Carboplatin) + 5-FU; Assigned to Arm(s): Chemotherapy alone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Trial to Compare Radiation Therapy Alone With Radiation Therapy and Concomitant Anti-EGFr Antibody (C225) for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if radiation therapy is more effective with or without cetuximab for cancer of the oropharynx, hypopharynx, or larynx.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without cetuximab in treating patients who have stage III or stage IV cancer of the oropharynx, hypopharynx, or larynx.


Options:
A: Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: Induction chemotherapy + concurrent chemoradiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy | Arm Label: Concurrent radiochemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy | Intervention Type: PROCEDURE; Name: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy; Assigned to Arm(s): Concurrent radiochemotherapy alone, Induction chemotherapy + concurrent chemoradiotherapy
C: Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II
D: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: Arm B: Cetuximab/Methotrexate/Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cetuximab, Drug: Methotrexate, Drug: Docetaxel | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Arm B: Cetuximab/Methotrexate/Docetaxel | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Arm B: Cetuximab/Methotrexate/Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Cetuximab/Methotrexate/Docetaxel

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: OBJECTIVES: I. Evaluate the safety of ascending doses of CPX administered to adult patients with mild cystic fibrosis.

II. Evaluate the pharmacokinetics of ascending doses of CPX in this patient population.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h
B: Arm Label: Cohort A: GLPG2222 50 mg once daily (QD); Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 50 mg, Drug: Placebo | Arm Label: Cohort A: GLPG2222 100 mg QD; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 100 mg, Drug: Placebo | Arm Label: Cohort B: GLPG2222 200 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GLPG2222 200 mg | Arm Label: Cohort B: GLPG2222 400 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GLPG2222 400 mg | Arm Label: Cohort A Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort B Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GLPG2222 50 mg; Assigned to Arm(s): Cohort A: GLPG2222 50 mg once daily (QD) | Intervention Type: DRUG; Name: GLPG2222 100 mg; Assigned to Arm(s): Cohort A: GLPG2222 100 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort A Placebo, Cohort A: GLPG2222 100 mg QD, Cohort A: GLPG2222 50 mg once daily (QD), Cohort B Placebo, Cohort B: GLPG2222 200 mg QD, Cohort B: GLPG2222 400 mg QD | Intervention Type: DRUG; Name: GLPG2222 200 mg; Assigned to Arm(s): Cohort B: GLPG2222 200 mg QD | Intervention Type: DRUG; Name: GLPG2222 400 mg; Assigned to Arm(s): Cohort B: GLPG2222 400 mg QD
C: Intervention Type: DRUG; Name: CPX; Assigned to Arm(s): N/A
D: Arm Label: Group 1 - 50 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 2 - 100 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 3 - 200 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 4 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: N91115 | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): Group 1 - 50 mg, Group 2 - 100 mg, Group 3 - 200 mg, Group 4 - Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: OBJECTIVES: I. Evaluate the safety of ascending doses of CPX administered to adult patients with mild cystic fibrosis.

II. Evaluate the pharmacokinetics of ascending doses of CPX in this patient population.


Options:
A: Intervention Type: DRUG; Name: CPX; Assigned to Arm(s): N/A
B: Arm Label: PTC124 PO; Type: EXPERIMENTAL; Interventions: Drug: PTC124 | Intervention Type: DRUG; Name: PTC124; Assigned to Arm(s): PTC124 PO
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Arm Label: Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg, Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated
Brief Summary: OBJECTIVES: I. Determine the effect of SYNSORB Pk therapy on mortality and frequency of severe extrarenal complications observed in children with acute stage E. coli-associated hemolytic uremic syndrome.

II. Determine the effect of SYNSORB Pk therapy on the need for the duration of dialysis in these patients.

III. Determine the effect of SYNSORB Pk therapy on the recovery of renal function and resolution of urinary abnormalities in these patients.


Options:
A: Arm Label: SYNSORB Pk; Type: EXPERIMENTAL; Interventions: Drug: SYNSORB Pk | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SYNSORB Pk; Assigned to Arm(s): SYNSORB Pk | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: cαStx1/cαStx2; Type: EXPERIMENTAL; Interventions: Drug: cαStx1/cαStx2 | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: cαStx1/cαStx2; Assigned to Arm(s): cαStx1/cαStx2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control
C: Arm Label: Admission/Intravascular Volume Expansion; Type: EXPERIMENTAL; Interventions: Drug: D5-0.9%NS | Arm Label: Outpatient Observation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Routine home oral rehydration | Intervention Type: DRUG; Name: D5-0.9%NS; Assigned to Arm(s): Admission/Intravascular Volume Expansion | Intervention Type: DRUG; Name: Routine home oral rehydration; Assigned to Arm(s): Outpatient Observation
D: Arm Label: Stage 1 - high treatment arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: INM004 | Arm Label: Stage 1 - Low treatment arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: INM004 | Arm Label: Stage 1 - Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Stage 2 - Selected active treatment arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: INM004 | Arm Label: Stage 2 - Placebo arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: INM004; Assigned to Arm(s): Stage 1 - Low treatment arm, Stage 1 - high treatment arm, Stage 2 - Selected active treatment arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Stage 1 - Placebo arm, Stage 2 - Placebo arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: OBJECTIVES:

I. Determine the safety and efficacy of a short course (72 hours) of intravenous acetylcysteine in patients with acute liver failure for whom no antidote or specific treatment is available.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: N-acetylcysteine (NAC); Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine (NAC) | Intervention Type: DRUG; Name: N-acetylcysteine (NAC); Assigned to Arm(s): N-acetylcysteine (NAC) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Sodium Bicarbonate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: OBJECTIVES: I. Evaluate the efficacy of fluoxetine on social and language deficits, global severity and compulsive dimensions of children and adolescents with autism.

II. Assess the effectiveness of this treatment regimen on neurocognitive deficits in this patient population.

III. Compare the baseline compulsive severity and treatment outcome in these patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: RO5028442 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: RO5028442; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A
C: Arm Label: Social Skills Focused CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Social Skills focused CBT | Arm Label: Stress Management/Relaxation Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress management/relaxation training | Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo drug | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: BEHAVIORAL; Name: Social Skills focused CBT; Assigned to Arm(s): Social Skills Focused CBT | Intervention Type: BEHAVIORAL; Name: Stress management/relaxation training; Assigned to Arm(s): Stress Management/Relaxation Training | Intervention Type: DRUG; Name: placebo drug; Assigned to Arm(s): placebo drug
D: Arm Label: DB Placebo Nasal Spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double blind phase Placebo Nasal Spray | Arm Label: DB Oxytocin Nasal Spray; Type: ACTIVE_COMPARATOR; Interventions: Drug: double Blind Oxytocin Nasal Spray | Arm Label: open label intranasal oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Open Label intranasal oxytocin | Intervention Type: DRUG; Name: Double blind phase Placebo Nasal Spray; Assigned to Arm(s): DB Placebo Nasal Spray | Intervention Type: DRUG; Name: double Blind Oxytocin Nasal Spray; Assigned to Arm(s): DB Oxytocin Nasal Spray | Intervention Type: DRUG; Name: Open Label intranasal oxytocin; Assigned to Arm(s): open label intranasal oxytocin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: OBJECTIVES: I. Evaluate the efficacy of fluoxetine on social and language deficits, global severity and compulsive dimensions of children and adolescents with autism.

II. Assess the effectiveness of this treatment regimen on neurocognitive deficits in this patient population.

III. Compare the baseline compulsive severity and treatment outcome in these patients.


Options:
A: Arm Label: Lurasidone 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone 20 mg daily | Arm Label: Lurasidone 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lurasidone 20 mg daily; Assigned to Arm(s): Lurasidone 20 mg | Intervention Type: DRUG; Name: Lurasidone; Assigned to Arm(s): Lurasidone 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: OBJECTIVES: I. Evaluate the efficacy of fluoxetine on social and language deficits, global severity and compulsive dimensions of children and adolescents with autism.

II. Assess the effectiveness of this treatment regimen on neurocognitive deficits in this patient population.

III. Compare the baseline compulsive severity and treatment outcome in these patients.


Options:
A: Arm Label: Transdermal nicotine first, placebo last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Arm Label: Transdermal placebo first, nicotine last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Intervention Type: DRUG; Name: Transdermal nicotine; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last | Intervention Type: OTHER; Name: Transdermal placebo; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last
B: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A
C: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: MPH Trial-Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: MPH Trial: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: Med Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Intervention Type: DRUG; Name: Methylphenidate-extended release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: DRUG; Name: Methylphenidate-immediate release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): MPH Trial-Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Occluded Artery Trial (OAT) - Randomized Comparative Effectiveness Trial of PCI and Medical Therapy Only Post MI
Brief Summary: The purpose of this study is to determine whether opening an occluded infarcted artery 3-28 days after an acute myocardial infarction in high-risk asymptomatic patients reduces the composite endpoint of mortality, recurrent myocardial infarction, and hospitalization for class IV congestive heart failure over an average 2.9-year follow-up with extended follow up for an average of six years. Long term follow-up of patients were completed in March 2010. Final collection of all regulatory documentation was completed June 2011.


Options:
A: Intervention Type: DRUG; Name: clopidogrel (SR25990C); Assigned to Arm(s): N/A
B: Arm Label: Optimal Medical Therapy Only (MED); Type: ACTIVE_COMPARATOR; Interventions: Drug: Beta adrenergic blockers, Drug: Platelet inhibitors, Drug: ACE Inhibitors | Arm Label: Percutaneous Coronary Intervention (PCI); Type: EXPERIMENTAL; Interventions: Drug: Beta adrenergic blockers, Drug: Platelet inhibitors, Procedure: PTCA and stents, Drug: ACE Inhibitors | Intervention Type: DRUG; Name: Beta adrenergic blockers; Assigned to Arm(s): Optimal Medical Therapy Only (MED), Percutaneous Coronary Intervention (PCI) | Intervention Type: DRUG; Name: Platelet inhibitors; Assigned to Arm(s): Optimal Medical Therapy Only (MED), Percutaneous Coronary Intervention (PCI) | Intervention Type: PROCEDURE; Name: PTCA and stents; Assigned to Arm(s): Percutaneous Coronary Intervention (PCI) | Intervention Type: DRUG; Name: ACE Inhibitors; Assigned to Arm(s): Optimal Medical Therapy Only (MED), Percutaneous Coronary Intervention (PCI)
C: Arm Label: gentamicin Group; Type: EXPERIMENTAL; Interventions: Drug: gentamicin-collagen sponge dipped in saline | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: gentamicin-collagen sponge dipped in saline; Assigned to Arm(s): gentamicin Group
D: Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin | Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): Enoxaparin

Answer: B